1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2011

Report date:

2011

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)

Principles of method if other than guideline:

The modified Local Lymph Node Assay (IMDS) was performed on 24 female NMRI mice of the strain Crl:NMRI BR (6 animals/test item group and 6 control animals) to determine if there is any specific (sensitizing) or non-specific (irritant) stimulating potential of the test item 1,3-Dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione.
The modifications refer to the measurement of cell proliferation by cell counting instead of radioactive labeling. In addition, the acute inflammatory skin reaction is determined to discriminate specific from non-specific activation of immune competent cells in the draining lymph nodes.

GLP compliance:

yes

Type of study:

mouse local lymph node assay (LLNA)

Test material

Test material information

Constituent 1

Reference substance name:

1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione

EC Number:

258-904-8

EC Name:

1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione

Cas Number:

53988-10-6

Molecular formula:

C8H8N2S

IUPAC Name:

1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione

Details on test material:

content: 99.2%

In vivo test system

Test animals

Species:

mouse

Strain:

NMRI

Sex:

female

Study design: in vivo (LLNA)

Vehicle:

dimethylformamide

Concentration:

Group 1 Vehicle (DMF)
Group 2 2% 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione (in DMF)
Group 3 10% 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione (in DMF)
Group 4 50% 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione (in DMF)
Group 5 30% Alpha Hexyl Cinnamic Aldehyde (in DMF)

No. of animals per dose:

6 animals/test item group and 6 control animals

Results and discussion

In vivo (LLNA)

Results

Results 1

Parameter:

SI

Remarks on result:

other: see Remark

Remarks:

A modified Local Lymph Node Assay (IMDS) was carried out in mice. The modifications refer to the measurement of cell proliferation by cell counting instead of radioactive labeling. Tabular summary of the LLNAlIMDS results 1. Direct LLNA (NMRI mice, female, 6 animals/group) Groups Weight index Cell count index (index of mean +/-SD in 0/0) Gr. 1 1.00 +/-22.25 1.00 +/-23.22 Gr. 2 1.01 +/-18.33 1.03 +/-62.60 Gr. 3 0.93 +/-22.57 0.97 +/-27.26 Gr. 4 1.19 +/-16.16 1.24 +/-24.50 Gr. 5 1.57s +/-19.95 1.78s +/-30.28 2. Ear swelling (NMRI mice, female, 6 animals/group, in 0.01 mm) Groups day 1 day 4 Index day 4 (mean +/-SD in %) Gr. 1 17.42 +/-2.96 17.67 +/-3.69 1.00 Gr. 2 16.75 +/-3.71 17.42 +/-4.55 0.99 Gr. 3 17.17 +/-4.18 17.50 +/-4.56 0.99 Gr. 4 17.42 +/-3.84 18.75 +/-6.48 1.06 Gr. 5 17.92 +/-3.73 22.67s +/-16.65 1.28 3. Ear weight (NMRI mice, female, 6 animals/group, in mg per 8 mm diameter punch) Groups day 4 Index day 4 (mean +/-SO in %) Gr. 1 11.84 +/-8.37 1.00 Gr. 2 11.11 +/-6.69 0.94 Gr. 3 10.93 +/-6.22 0.92 Gr. 4 12.01 +/-7.48 1.01 Gr. 5 14.66s +/-14.90 1.24 s = statistically significant increase (p< 0.05) Group 1 Vehicle (DMF) Group 2 2% 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione (in DMF) Group 3 10% 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione (in DMF) Group 4 50% 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione (in DMF) Group 5 30% Alpha Hexyl Cinnamic Aldehyde (in DMF)

Results 2

Parameter:

other: disintegrations per minute (DPM)

Remarks on result:

other: not applicable

Any other information on results incl. tables

Based on results obtained in validation studies and general experiences with this test system groups of mice were treated with vehicle, 2 %, 10 % or 50 % 1 ,3-Dihydro-4( or 5)-methyl-2H-benzimidazole-2-thione in DMF.

The NMRI mice did not show an increase in the stimulation indices for cell counts or for weights of the draining lymph nodes after application of the test item 1 ,3-Dihydro-4( or 5)-methyl-2H-benzimidazole-2-thione.

The "positive level", which is 1.4 for the cell count index, was never reached or exceeded in any dose group.

The "positive level" of ear swelling, which is 2x 10E-2 mm increase, i.e. about 10 % of the control values, has not been reached or exceeded in any dose group.

In the high dose group deposits of the test item were standing at the ears of one animal (no. 24), in places.

After treatment with Alpha Hexyl Cinnamic Aldehyde (group 5) the NMRI mice showed clear increases in the weights of the draining lymph nodes and in the stimulation indices for cell counts compared to control animals, which are of statistical significance. The "positive level", which is 1.4 for cell count indices, has clearly been exceeded.

The "positive level" of ear swelling, which is 2x10E-2 mm increase, i.e. about 10 % of the control values, has been exceeded in the positive control group. This increase was of statistical significance. A significant increase compared to vehicle treated animals regarding ear weights was detected, too.

It has to be clarified that the "positive levels" mentioned above are exclusively defined for the NMRI outbreed mice used for this study Such positive limits have to be calculated for each strain of mice individually.

Applicant's summary and conclusion

Interpretation of results:

not sensitising

Remarks:

Migrated information

Executive summary:

The modified Local Lymph Node Assay (IMDS) was performed on 24 female NMRI mice of the strain HsdWin:NMRI (6 animals/ test item group and 6 control animals) to determine if there is any specific (sensitizing) or non-specific (irritant) stimulating potential of

the test item 1 ,3-Dihydro-4( or 5)-methyl-2H-benzimidazole-2-thione.

A concurrent control of 6 animals treated with Alpha Hexyl Cinnamic Aldehyde was included.

The study was conducted with the following test item concentrations:

Test item: 0 % (vehicle control), 2 %, 10 % and 50 %. Positive control: 30 % Alpha Hexyl Cinnamic Aldehyde

The test item was formulated in dimethylformamide (DMF) to yield a solution in the low and mid dose and a suspension in the high dose. The positive control was formulated in DMF to yield a solution.

Compared to vehicle-treated animals, none of the parameters measured in the substancetreated groups, i.e. cell counts and weights of the draining lymph nodes, ear weights and ear swelling, reached or exceeded the "positive levels" defined for this assay [6, 8, 9]. These results show that there is no indication for a skin sensitizing effect after administration of a concentration up to and including 50 % 1,3-Dihydro-4(or 5)-methyl-2H-benzimidazole-2- thione in this test system.

In conclusion, these results show that the test item 1,3-Dihydro-4(or 5)-methyl-2Hbenzimidazole- 2-thione was not sensitising in mice after dermal application of up to and including a 50 % concentration. No indication for a non-specific (irritant) activation was

detected, too. Therefore, the concentration of 50 % turned out to be the NOEL for the parameters investigated in this study with respect to skin sensitization.

These results are verified by the comparison with the results of the positive control group (Alpha Hexyl Cinnamic Aldehyde).